139 related articles for article (PubMed ID: 10568429)
21. Structural aspects of interactions within the Myc/Max/Mad network.
Nair SK; Burley SK
Curr Top Microbiol Immunol; 2006; 302():123-43. PubMed ID: 16620027
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional regulation. Flipping the Myc switch.
Bernards R
Curr Biol; 1995 Aug; 5(8):859-61. PubMed ID: 7583141
[TBL] [Abstract][Full Text] [Related]
23. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.
Blackwood EM; Eisenman RN
Science; 1991 Mar; 251(4998):1211-7. PubMed ID: 2006410
[TBL] [Abstract][Full Text] [Related]
24. Wnt1 inducible signaling pathway protein-3 regulation and microsatellite structure in arthritis.
Cheon H; Boyle DL; Firestein GS
J Rheumatol; 2004 Nov; 31(11):2106-14. PubMed ID: 15517620
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha.
Redlich K; Kiener HP; Schett G; Tohidast-Akrad M; Selzer E; Radda I; Stummvoll GH; Steiner CW; Gröger M; Bitzan P; Zenz P; Smolen JS; Steiner G
Arthritis Rheum; 2001 Feb; 44(2):266-74. PubMed ID: 11229456
[TBL] [Abstract][Full Text] [Related]
26. Detection of oncofetal h19 RNA in rheumatoid arthritis synovial tissue.
Stuhlmüller B; Kunisch E; Franz J; Martinez-Gamboa L; Hernandez MM; Pruss A; Ulbrich N; Erdmann VA; Burmester GR; Kinne RW
Am J Pathol; 2003 Sep; 163(3):901-11. PubMed ID: 12937131
[TBL] [Abstract][Full Text] [Related]
27. Expression of the precursor of secretoneurin, secretogranin II, in the synovium of patients with rheumatoid arthritis and osteoarthritis.
Sprott H; Pap T; Rethage J; Wintersberger W; Gay RE; Bradley LA; Uebelhart D; Gay S
J Rheumatol; 2000 Oct; 27(10):2347-50. PubMed ID: 11036828
[TBL] [Abstract][Full Text] [Related]
28. Alternative splicing and embryonic expression of the Xenopus mad4 bHLH gene.
Newman CS; Krieg PA
Dev Dyn; 1999 Jun; 215(2):170-8. PubMed ID: 10373021
[TBL] [Abstract][Full Text] [Related]
29. Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis.
van Lent PL; Span PN; Sloetjes AW; Radstake TR; van Lieshout AW; Heuvel JJ; Sweep CG; van den Berg WB
Ann Rheum Dis; 2005 Mar; 64(3):368-74. PubMed ID: 15485996
[TBL] [Abstract][Full Text] [Related]
30. Design and properties of a Myc derivative that efficiently homodimerizes.
Soucek L; Helmer-Citterich M; Sacco A; Jucker R; Cesareni G; Nasi S
Oncogene; 1998 Nov; 17(19):2463-72. PubMed ID: 9824157
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of conventional and real-time RT-PCR for the quantitation of jun protooncogene mRNA and analysis of junB mRNA expression in synovial membranes and isolated synovial fibroblasts from rheumatoid arthritis patients].
Huber R; Kunisch E; Glück B; Egerer R; Sickinger S; Kinne RW
Z Rheumatol; 2003 Aug; 62(4):378-89. PubMed ID: 12928942
[TBL] [Abstract][Full Text] [Related]
32. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1.
Pulverer B; Sommer A; McArthur GA; Eisenman RN; Lüscher B
J Cell Physiol; 2000 Jun; 183(3):399-410. PubMed ID: 10797315
[TBL] [Abstract][Full Text] [Related]
33. Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants.
Mukherjee B; Morgenbesser SD; DePinho RA
Genes Dev; 1992 Aug; 6(8):1480-92. PubMed ID: 1644290
[TBL] [Abstract][Full Text] [Related]
34. A dominant-negative mutant of Max that inhibits sequence-specific DNA binding by Myc proteins.
Billaud M; Isselbacher KJ; Bernards R
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2739-43. PubMed ID: 8464883
[TBL] [Abstract][Full Text] [Related]
35. Sequential expression of the MAD family of transcriptional repressors during differentiation and development.
Quéva C; Hurlin PJ; Foley KP; Eisenman RN
Oncogene; 1998 Feb; 16(8):967-77. PubMed ID: 9519870
[TBL] [Abstract][Full Text] [Related]
36. Myc meets its Max.
Cole MD
Cell; 1991 May; 65(5):715-6. PubMed ID: 2040011
[No Abstract] [Full Text] [Related]
37. Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1.
Lahoz EG; Xu L; Schreiber-Agus N; DePinho RA
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5503-7. PubMed ID: 8202517
[TBL] [Abstract][Full Text] [Related]
38. Myc and Max: molecular evolution of a family of proto-oncogene products and their dimerization partner.
Atchley WR; Fitch WM
Proc Natl Acad Sci U S A; 1995 Oct; 92(22):10217-21. PubMed ID: 7479755
[TBL] [Abstract][Full Text] [Related]
39. The Myc/Max/Mad network and the transcriptional control of cell behavior.
Grandori C; Cowley SM; James LP; Eisenman RN
Annu Rev Cell Dev Biol; 2000; 16():653-99. PubMed ID: 11031250
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells.
Larsson LG; Bahram F; Burkhardt H; Lüscher B
Oncogene; 1997 Aug; 15(6):737-48. PubMed ID: 9264414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
